The vice president of Neuroscience and Vaccines at Takeda discusses the clinical significance of oveporexton's FDA approval and how restoring orexin signaling may reshape treatment expectations in narcolepsy type 1. [WATCH TIME: 4 minutes]
Sara Sarkey, PhD
Advertisement
Articles by Sara Sarkey, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Grants Fast Track Designation to T-Cell Agent CK0803 for ALS
2
AHA/ASA Issue New Guideline for Adult Stroke Rehabilitation and Recovery
3
Evaluating Once-Yearly Salanersen Across the Spinal Muscular Atrophy Spectrum: A Phase 3 Clinical Program
4
FDA Clears Roche's Single-Biomarker Elecsys pTau217 Blood Test for Alzheimer Disease
5